Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
DARE similar filings
- 14 Nov 22 Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study
- 9 Nov 22 Results of Operations and Financial Condition
- 3 Nov 22 Regulation FD Disclosure
- 17 Oct 22 Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study
- 11 Oct 22 Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive Product
- 9 Sep 22 Other Events
- 29 Aug 22 Daré Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
Filing view
External links